Request Demo
Last update 09 Sep 2025
Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center)
Last update 09 Sep 2025
Overview
Basic Info
Drug Type Small molecule drug, Liposomal Drug |
Synonyms PNU-93914 |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center)NCT05691010
A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer
NCT04722523
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT03085056
A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
100 Clinical Results associated with Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center)
Login to view more data
100 Translational Medicine associated with Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center)
Login to view more data
100 Patents (Medical) associated with Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center)
Login to view more data
100 Deals associated with Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic Esophageal Carcinoma | Phase 2 | United States | 01 Dec 2000 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Endometrial Carcinoma PD-L1 | dMMR | pMMR | - | Pembrolizumab plus carboplatin/paclitaxel | ytakrkshkp(uhcnagefvv) = xasejuzadf aoadhahzsm (gzobpzponh ) | - | 01 Nov 2024 | |
Carboplatin/paclitaxel plus placebo | ytakrkshkp(uhcnagefvv) = gnzlfekgcn aoadhahzsm (gzobpzponh ) | ||||||
Not Applicable | 512 | T-DM1 arm | gsxcfcjzwp(goyrqqycqz) = iqqyqgfvxy xqrixkkyos (sxmwfsxwfi ) View more | - | 15 Feb 2020 | ||
TH arm | gsxcfcjzwp(goyrqqycqz) = ltgbayjfas xqrixkkyos (sxmwfsxwfi ) View more | ||||||
Phase 2 | 108 | nnsxnefrpa(jrrxcjvzlf): HR = 0.945 (95% CI, 0.625 - 1.428) View more | Negative | 01 Jun 2016 | |||
Paclitaxel + Reolysin 3 × 10^10 TCID50 | |||||||
Phase 2 | 44 | qckibebdzf = lgsxghseer xnouagsogp (bqwhkdhcvh, hqbounhqgh - holsjvmroq) View more | - | 30 Dec 2015 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free